Your session is about to expire
← Back to Search
Monoclonal Antibodies
TTX-030 for Lymphoma
Phase 1
Waitlist Available
Research Sponsored by Trishula Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
Study Summary
This trial is testing a new antibody that may help the immune system better fight cancer by reducing immunosuppressive adenosine and increasing pro-inflammatory adenosine triphosphate.
Eligible Conditions
- Lymphoma
- Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Recommended Phase 2 Dose (RP2D)
Secondary outcome measures
Anti-tumor activity
CD39 Expression
Maximum Plasma Concentration (Cmax)
Trial Design
3Treatment groups
Experimental Treatment
Group I: Arm 4, Chemotherapy CombinationExperimental Treatment3 Interventions
TTX-030 plus gemcitabine plus nab-paclitaxel
Group II: Arm 2, Anti-PD-1 CombinationExperimental Treatment2 Interventions
TTX-030 plus pembrolizumab
Group III: Arm 1, Single AgentExperimental Treatment1 Intervention
TTX-030
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TTX-030
2019
Completed Phase 1
~60
Pembrolizumab
2017
Completed Phase 2
~2010
Gemcitabine
2017
Completed Phase 3
~2070
nab paclitaxel
2008
Completed Phase 2
~190
Find a Location
Who is running the clinical trial?
Trishula Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
365 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have had an allergic reaction or are very sensitive to any of the ingredients in the study treatment.You have used any experimental drugs within the last 28 days before starting this study and you cannot use them during the study.You can receive a medication called docetaxel as part of your regular treatment.You have a serious, ongoing health issue or another type of cancer that needs treatment.You have a history of a serious autoimmune disease.You have a type of cancer that has spread or has come back after treatment.You have had a severe allergic reaction to any kind of medication called a monoclonal antibody.You are able to receive pembrolizumab alone as the standard treatment.You have advanced pancreatic cancer and can receive the standard treatment of gemcitabine plus nab-paclitaxel.You are currently taking strong medications that weaken your immune system.
Research Study Groups:
This trial has the following groups:- Group 1: Arm 2, Anti-PD-1 Combination
- Group 2: Arm 1, Single Agent
- Group 3: Arm 4, Chemotherapy Combination
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger